ENHANCED Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia immune activation was observed with frontline dasatinib plus blinatumomab compared with ponatinib plus blinatumomab, according to detailed immune analyses from a large clinical cohort. Study Design and Immune AssessmentThe investigation examined immune changes in patients with Philadelphia chromosome positive acute lymphoblastic leukaemia treated with either dasatinib plus blinatumomab or ponatinib plus blinatumomab. Data from 153 patients were analysed, including 43 treated with dasatinib plus blinatumomab and 110 treated with ponatinib plus blinatumomab. Leukaemia Immune ActivationPh+ acute lymphoblastic leukaemia immune activation was especially evident in the natural killer and natural killer T cell compartments. Durable Immune Effects and Clinical ImplicationsFunctional assessments revealed a significantly enhanced natural killer cell capacity in patients treated with dasatinib plus blinatumomab compared with ponatinib treated patients.